OKYO Pharma Limited's (LON:OKYO)(OTCQB:EMMLF) CEO Dr Gary Jacob tells Proactive's Andrew Scott they've engaged Ora Inc, a world-class ophthalmology contract research organization, to guide the upcoming product development and lead the regulatory strategy for OK-101.
The drug is OKYO's lead pre-clinical compound and is being developed for the treatment of dry eye.